Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accent MicrocellNSE:ACCENTMIC -2.17%47 Return-on-Tangible-Equity is 18.65% as of Mar. 2026, which is 4% below its 10-year median of 19.40. GuruFocus rates NSE:ACCENTMIC with a GF Score™ of 47/100. The stock has 6 warning signs investors should review. Among 900 Drug Manufacturers companies, Accent Microcell ranks better than 76.67% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Accent Microcell's annualized net income for the quarter that ended in Mar. 2026 was ₹439 Mil. Accent Microcell's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹2,351 Mil. Therefore, Accent Microcell's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 18.65%.
The historical rank and industry rank for Accent Microcell's Return-on-Tangible-Equity or its related term are showing as below:
NSE:ACCENTMIC'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 18.15 Med: 19.4 Max: 30.04
Current: 18.65
During the past 6 years, Accent Microcell's highest Return-on-Tangible-Equity was 30.04%. The lowest was 18.15%. And the median was 19.40%.
NSE:ACCENTMIC's Return-on-Tangible-Equity is ranked better than 76.67% of 900
companies
in the Drug Manufacturers industry
Industry Median: 7.925
vs NSE:ACCENTMIC: 18.65
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Accent Microcell Return-on-Tangible-Equity Related Terms
Accent Microcell Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Accent Microcell's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ACCENTMIC vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Accent Microcell's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accent Microcell Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accent Microcell's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Accent Microcell's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is one times the annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 18.65% mean?
Accent Microcell (NSE:ACCENTMIC) has a Return-on-Tangible-Equity of 18.65% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Accent Microcell and its competitors. This is near median its historical median of 19.40. Over the past decade, Accent Microcell's Return-on-Tangible-Equity has ranged from 18.15 to 30.04. According to the industry distribution chart, Accent Microcell ranks #210 out of 900 companies in the Drug Manufacturers industry, placing it in the top 23.3%.
Is Accent Microcell's Return-on-Tangible-Equity too high?
Accent Microcell's current Return-on-Tangible-Equity of 18.65% is near median its 10-year median of 19.40. Over the past 10 years, this metric has ranged from a low of 18.15 to a high of 30.04. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.93. Accent Microcell's value of 18.65% is 135.3% above this industry median. Based on the distribution chart, Accent Microcell ranks #210 out of 900 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Accent Microcell has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Accent Microcell's Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Accent Microcell ranks #210 out of 900 companies for Return-on-Tangible-Equity. This places Accent Microcell in the top 23% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.93. Accent Microcell's value of 18.65% is 135.3% above this benchmark. Historically, Accent Microcell's own Return-on-Tangible-Equity has ranged from 18.15 to 30.04 over the past decade. While the company's 10-year median is 19.40 vs. the industry median of 7.93, Accent Microcell has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.93, based on 900 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accent Microcell's current Return-on-Tangible-Equity of 18.65% is 135.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Accent Microcell and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accent Microcell's current Return-on-Tangible-Equity is 18.65%, which is near median its own 10-year median of 19.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accent Microcell stock overvalued right now?
Accent Microcell (NSE:ACCENTMIC) has a current Return-on-Tangible-Equity of 18.65%. The current Return-on-Tangible-Equity is 18.65%, which is near median its 10-year median of 19.40 and 135.3% above the Drug Manufacturers industry median of 7.93. Accent Microcell's overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Accent Microcell (NSE:ACCENTMIC), the current Return-on-Tangible-Equity is 18.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accent Microcell Ltd is engaged in the manufacturing business of pharmaceutical excipients including products like Microcrystalline Cellulose which is a term for refined wood pulp and is used as a texturizer, an anti-caking agent, a fat substitute, an emulsifier, an extender, and a bulking agent in food production; Croscarmellose Sodium used as a super disintegrant in pharmaceutical formulations; Magnesium Stearate; Cellulose Powder, and others. Its business segments are segregated based on the location of its manufacturing facilities and include Dahej (SEZ Unit), Pirana, Unit III, and Inter Unit Sales. Geographically, a majority of the company's revenue is derived through the export of its products to various countries.
47GF Score
Get the complete analysis for NSE:ACCENTMIC
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ACCENTMIC has been successfully added to your 
